Cosmetic Safety Enhancement Act Advances In US House, Still Without Preemption
Approved by the House Energy and Commerce Health Subcommittee on 11 March, H.R. 5279 still lacks any concrete provisions regarding federal preemption of state and local requirements, though bill author and full committee chair Frank Pallone, D-NJ, remains committed to discussions on the subject. He recognized preemption as “a major issue that I know we have to deal with.”
You may also be interested in...
Bundled within the draft FDA Safety and Landmark Enhancements Act are federal cosmetics reform provisions that would require facility registration and product listings with the US FDA, adverse event reporting and good manufacturing practices, while empowering the agency to order product recalls, access company records, and suspend dangerous operations.
After freezing its routine inspection activities at the height of the COVID-19 pandemic, the FDA adapted its oversight approach visibly in the drug and medical devices sectors, including with voluntary remote regulatory assessments. The agency now seeks authority to continue that work on a non-voluntary basis across all FDA-regulated programs.
Ostensibly taking cues from California and lessons from previous congressional sessions, US lawmakers, NGOs and “forward-thinking cosmetics companies” seek piecemeal cosmetics reform via four federal bills slated for introduction in the coming week.